Previous Blogs

Avatar

By Jia Min Boo

August 06, 2020

In 2011, the US FDA issued an advisory regarding the potential formation of glass lamellae in vials containing injectable drugs. This was in response to several drug recalls in 2010-11. The number of glass-related drug recalls has since declined greatly. This no doubt is due to key actions taken by pharmaceutical manufacturers before the drug goes to market, even during the development phases.

Avatar

By James McCaw

June 08, 2020

West’s Integrated Solutions program brings together all West’s products/services and industry knowledge into customer-focused solutions that Simplify the Journey™. One aspect of Integrated Solutions is wide-ranging analytical services, which includes state-of-the-art container closure integrity (CCI) capabilities. Understanding CCI as it relates to industry expectations, manufacturing, and regulations can be a challenge.

Avatar

By Jen Riter

November 22, 2019

Combination products open up new vistas when it comes to delivering innovative therapies to patients in need, but teams bringing these products to the market face a number of significant hurdles. Recent surveys conducted by West at workshops held in PA and AZ have revealed some of our customers’ biggest challenges. This is the first of three blogs focused on these challenges — and how West can help Simplify the Journey™ when it comes to developing a combination product.

Avatar

By Jessie Zhang

June 20, 2019

At the recent CPhI China Conference, we introduced our Integrated Solutions Program to the Asia Pacific Market. The Program is designed to help reduce risk, mitigate regulatory complexity and Simplify the Journey™ from molecule to market for our pharmaceutical partners.

Avatar

By Victoria Morgan

May 16, 2019

Biologic drugs, rather than being synthesized from other compounds, are generally made using human or animal proteins. At the molecular level, they’re usually larger and much more complex than regular drugs. Routine oral administration of biologics has not been mastered as there is enzymatic and pH-dependent degradation of drugs in the stomach and intestines. Low permeability of epithelial cells that line the gastrointestinal tract means that proteins and peptides typically have extremely low bioavailability in the range of around 0-2% when taken by mouth.

Avatar

By Victoria Morgan

May 07, 2019

Before an injectable biologic can be formulated and manufactured, an extensive series of pre-formulation checks are necessary to ensure that developers avoid formulating an unstable, non-viable product¹. Developers must determine whether the injectable biologic will break down within the intended formulation or the manufacturing process. The drug must be thermally stable, possibly resistant to oxidation, tolerate variations in light, and other environmental stresses placed on it during manufacturing and packaging.